C4 Therapeutics, Inc.
CCCCNASDAQHealthcare● Active
$3.73
+$0.14(+3.76%)
Market Cap$308531275
P/E Ratio—
52W High$4.598
52W Low$1.36
C4 Therapeutics, Inc. (CCCC) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CCCC · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($104.99M) | ($105.32M) | ($132.49M) | ($128.18M) | ($83.89M) |
| Depreciation & Amort. | $1.96M | $1.82M | $1.88M | $1.68M | $1.49M |
| Stock-Based Comp. | $19.10M | $29.66M | $27.23M | $30.02M | $21.51M |
| Change in Working Capital | ($29.28M) | $7.65M | ($6.94M) | ($16.78M) | ($30.09M) |
| Net Cash from Operations | ($98.69M) | ($65.16M) | ($106.84M) | ($105.94M) | ($86.97M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.61M) | ($0.18M) | ($1.71M) | ($5.50M) | ($1.28M) |
| Purchases of Investments | ($227.07M) | ($284.32M) | ($129.90M) | ($219.53M) | ($537.74M) |
| Sales of Investments | $219.08M | $233.23M | $289.95M | $283.44M | $349.68M |
| Net Cash from Investing | ($8.60M) | ($51.27M) | $158.35M | $58.42M | ($189.34M) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.19M) | ($0.19M) | ($0.11M) | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | ($12.50M) | $0.00M | $0.00M |
| Net Cash from Financing | $126.40M | $45.34M | $45.49M | $1.15M | $171.40M |
| Free Cash Flow | |||||
| Free Cash Flow | ($99.30M) | ($65.34M) | ($108.55M) | ($111.44M) | ($88.24M) |
| FCF Margin %(computed) | -276.24% | -183.61% | -522.96% | -358.36% | -192.73% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more C4 Therapeutics, Inc. data
About C4 Therapeutics, Inc. (CCCC) Cash Flow Statement
C4 Therapeutics, Inc. generated operating cash flow of ($0.10B) and free cash flow of ($0.10B) for 2025 — a FCF margin of -276.24%. Capital expenditure was ($0.00B).
Frequently asked questions
CCCC · 4 questionsC4 Therapeutics, Inc. generated free cash flow of ($0.10B) for 2025, down 52.0% year-over-year.
CCCC free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10